EMEA-001868-PIP03-16
Key facts
| Active substance |
Selonsertib
|
| Therapeutic area |
Gastroentology-Hepatology
|
| Decision number |
P/0252/2017
|
| PIP number |
EMEA-001868-PIP03-16
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Treatment of non-alcoholic steatohepatitis (NASH)
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Gilead Sciences International Ltd
Tel. +44 (0)1223 897300
E-mail: regulatory.pip@gilead.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|